Dual PPARα/γ agonists hold promise to be able to combine the properties of TZDs and fibrates, as well as improve the management of type 2 diabetes and provide an effective therapeutic option for treating the multifactorial components of cardiovascular disease, metabolic syndrome [43], and even cancer. The gene discussed is PPARA; the disease is cancer.